The Medicine Forum
Volume 14

Article 10

2013

Sudden Onset Blindness in a Patient with Mixed
Connective Tissue Disease
Chris Terry, MSIII
Thomas Jefferson University

Prachi Thanawala, MD
Thomas Jefferson University Hospitals, Prachi.Thanawala@jefferson.edu

Erika Villanueva, MD
Thomas Jefferson University Hospitals

Follow this and additional works at: https://jdc.jefferson.edu/tmf
Part of the Medicine and Health Sciences Commons

Let us know how access to this document benefits you
Recommended Citation
Terry, MSIII, Chris; Thanawala, MD, Prachi; and Villanueva, MD, Erika (2013) "Sudden Onset Blindness in a Patient with Mixed
Connective Tissue Disease," The Medicine Forum: Vol. 14 , Article 10.
DOI: https://doi.org/10.29046/TMF.014.1.010
Available at: https://jdc.jefferson.edu/tmf/vol14/iss1/10

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
The Medicine Forum by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Terry, MSIII et al.: Sudden Onset Blindness in a Patient with Mixed Connective Tissue Disease

The Medicine Forum

Sudden Onset Blindness in a Patient with Mixed
Connective Tissue Disease
Chris Terry, MSIII, Prachi Thanawala, MD, Erika Villanueva, MD

Case Presentation
A 66-year-old Caucasian female recently diagnosed with mixed
connective tissue disease presented with acute onset vision loss
in the left eye. The patient first noted a “hazy-shower” that
caused blurry vision with loss of peripheral vision. Her vision
progressively worsened over a four-day period, resulting in
complete blindness in the left eye and the onset of blurry vision
in her right eye. She denied any eye pain, discharge, photophobia
or similar symptoms in the past. The patient did note a very
mild headache for four days but denied any other symptoms.

Investigations
The patient was admitted for workup of left eye vision loss.
Rheumatology was consulted for concern of autoimmune
vasculitis, and the patient was started on IV methylprednisolone
(1g daily). There was a concern for giant cell arteritis (GCA).
Therefore bilateral temporal artery biopsies were obtained.
The biopsy specimens showed no signs of GCA; however some
ophthalmic artery occlusion was noted. There was concern for
further thromboses, so MRI, MRA, and MRV of the head, CT
of the chest, abdomen and pelvis, ultrasound of the carotid
arteries, and trans-esophageal echocardiogram were performed.
However, all of these imaging studies were non-diagnostic.
The patient had an Orbital Duplex Scan that showed
significantly reduced blood flow to both eyes. Laboratory
testing for autoimmune markers were significant for a positive
rheumatoid factor (RF) and positive anti-cyclic citrullinated
protein (anti-CCP) antibody (Ab). An ANA screen was positive
with a titer of 1:80. Anti-ssDNA and anti-dsDNA antibodies
were both moderately elevated. All other studies were
non-diagnostic including anti-Smith Ab, RNP Ab, anti-SS-A
Ab, anti-SS-B Ab, C-reactive protein, erythrocyte sedimentation
rate, cryoglobulins, C-ANCA, P-ANCA.

Differential Diagnosis
Vasculitides are defined by the presence of inflammatory
leukocytes in vessel walls with reactive damage to mural
structures and may occur as a primary process or secondary to
another underlying disease.1 There was initial concern for GCA
due to the age of onset, presence of headaches, and absence of
other symptoms. However, the bilateral temporal artery biopsies
were negative. Essential cryoglobulinemic vasculitis was also
considered; however it was ruled out based on the absence of
serum cryoglobulins.
Given the patient’s past medical history and positive ANA,
the medical team suspected an underlying connective tissue
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disorder. Additionally, due to the absence of serum ANCAs,
the differential diagnosis was narrowed to a non-ANCA
vasculitides. An important differential to bear in mind is
systemic lupus erythematosus (SLE), a chronic, autoimmune
connective tissue disorder affecting multiple organ systems
often with a relapsing and remitting clinical course. Ocular
manifestations, occurring in up to one third of patients, result
from localized ischemia.2,3 Lupus retinopathy is one of the most
common vision-threatening complications of SLE, occurring in
up to 29% of patients.6-8
Another etiology to consider is rheumatoid arthritis (RA). Blood
vessel inflammation is a central feature of RA.9 The mean onset
of vasculitic symptoms is 13.6 years after the initial diagnosis
of RA, and patients typically have developed rheumatoid
nodules. 10,11 The two principal ocular manifestations of
rheumatoid vasculitis are episcleritis and peripheral ulcerative
keratitis.12,13 The presence of an elevated RF and positive ANA,
as well as a past medical history of nodular episcleritis, led to a
high clinical suspicion for rheumatoid vasculitis.

Treatment
Rheumatology and Ophthalmology agreed to continue the IV
methylprednisolone. On hospital day four, the patient was given
cyclophosphamide (750 mg/m2) to be dosed monthly. This
decision was based primarily on two critical studies investigating
the efficacy and safety of pulse IV cyclophosphamide.
In mildly progressive ocular inflammation, therapy is often
initiated with immunomodulatory agents prior to pulse IV
cyclophosphamide. However, with failed immunomodulatory
therapy or rapidly progressing inflammation at presentation,
initiation of pulse IV cyclophosphamide is warranted. In 2004,
Durrani et al. demonstrated the control of inflammation and
steroid-sparing effect of pulse IV cyclophosphamide in 38
patients with severe ocular inflammation of diverse etiologies.14
Cyclophosphamide is a non-specific alkylating agent that exerts
a cytotoxic effect on rapidly proliferating cells. It has shown
remarkable safety in the rheumatologic and dermatologic
literature when used IV for limited periods.15,16

Outcome and Follow-up
The patient continued on methylprednisolone (1g daily) for
a total of eight days. On hospital day nine, her daily dose of
methylprednisolone was decreased to 250 mg. At this time,
her vision was stable in the right eye; however she still had
complete loss of vision and light perception in her left eye. On
hospital day ten, her steroid dose was adjusted to prednisone
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(100 mg daily), which she would continue until her next dose
of cyclophosphamide. The patient had a repeat Orbital Duplex
scan on hospital day ten which showed stable parameters in
the central retinal artery of the right eye and improved flow in
the temporal vessel of the short posterior ciliary system in the
left eye. On hospital day 11, the patient was medically stable
for discharge with close follow up with Ophthalmology, Retina
Clinic, and Rheumatology.
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